Jasper Therapeutics Says Health Canada Cleared Phase 1b/2a Briquilimab Asthma Study
Jasper Therapeutics (JSPR) said Tuesday that Health Canada has cleared its clinical trial application for a phase 1b/2a asthma challenge study assessing briquilimab, an antibody therapy for mast cell-driven diseases.
The phase 1b/2a asthma study is expected to enroll 30 patients across 10 sites in Canada and the European Union, aiming to validate briquilimab's efficacy, with dosing beginning in Q4 and results expected in H2 2025, the company said.
The biotechnology company also said its c-Kit Mouse model has received a registered trademark from the US Patent and Trademark Office for its ability to test c-Kit or CD117 inhibitors in various diseases.
Price: 18.92, Change: -0.38, Percent Change: -1.97
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。